Synthesis of low immunogenicity RNA with high-temperature in vitro transcription
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The use of synthetic RNA for therapeutics requires that the in vitro synthesis process be robust and efficient. The technology used for the synthesis of these in vitro - transcribed RNAs, predominantly using phage RNA polymerases (RNAPs), is well established. However, transcripts synthesized with RNAPs are known to display an immune-stimulatory activity in vivo that is often undesirable. Previous studies have identified double-stranded RNA (dsRNA), a major by-product of the in vitro transcription (IVT) process, as a trigger of cellular immune responses. Here we describe the characterization of a high-temperature IVT process using thermostable T7 RNAPs to synthesize functional mRNAs that demonstrate reduced immunogenicity without the need for a post-synthesis purification step. We identify features that drive the production of two kinds of dsRNA by-products—one arising from 3′ extension of the run-off product and one formed by the production of antisense RNAs—and demonstrate that at a high temperature, T7 RNAP has reduced 3′-extension of the run-off product. We show that template-encoded poly(A) tailing does not affect 3′-extension but reduces the formation of the antisense RNA by-products. Combining high-temperature IVT with template-encoded poly(A) tailing prevents the formation of both kinds of dsRNA by-products generating functional mRNAs with reduced immunogenicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have identified dsRNA byproducts as a trigger of cellular immune responses, and therefore removing dsRNA from mRNA reduces reactogenicity and improves protein translation.10,11”
From Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses (2024) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K. J., et al. (2006) · Nature · doi:10.1038/nature04734 · Cited by 3,888 · cited 1×
“Introduction of transcripts synthesized using T7 RNAP has been shown to activate cytosolic sensors, such as RIG-I and MDA5, that activate the innate immune system in response to viral double-stranded RNAs (dsRNAs) [17-19].”
BackgroundKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · cited 1×
“Incorporation of modified nucleosides into synthetic mRNA mitigates the immune response to some extent by mimicking endogenous mRNAs (Karikó et al. 2005; Durbin et al. 2016; Pardi et al. 2017; Richner et al. 2017; Freund et al. 2019).”
BackgroundmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · cited 1×
“However, it is also known that introduction of synthetic in vitro transcribed mRNAs into cells or animal models results in an immune response against the synthetic molecules [1-5].”
BackgroundRIG-I-mediated antiviral responses to single-stranded RNA bearing 5’-phosphates
Pichlmair, A., Schulz, O., Tan, C. P., Näslund, T. I., Liljeström, P., Weber, F., & Reis e Sousa, C. (2006) · Science · doi:10.1126/science.1132998 · Cited by 2,210 · cited 1×
“Introduction of transcripts synthesized using T7 RNAP has been shown to activate cytosolic sensors, such as RIG-I and MDA5, that activate the innate immune system in response to viral dsRNA (Katoet al. 2006; Pichlmair et al. 2006;Goubauet al. 2014).”
BackgroundKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · cited 1×
“Furthermore, to ensure that we are measuring the immune response exclusively from the dsRNA byproducts, we introduced pseudouridine modifications in the mRNAs to evade immune response from TLR7 and TLR8 [7, 37].”
MethodmRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062 · cited 2×
“However, it is also known that introduction of synthetic in vitro transcribed mRNAs into cells or animal models results in an immune response against the synthetic molecules [1-5].”
BackgroundKarikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898 · cited 3×
“A common approach for removing double-stranded by-products is to use a chromatography-based purification step after completion of the synthesis reaction (Karikó et al. 2011;Weissman et al. 2013).”
BackgroundMethodA facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates
Goubau, D., Schlee, M., Deddouche, S., Pruijssers, A. J., Zillinger, T., Goldeck, M., Schuberth, C., Van der Veen, A. G., Fujimura, T., Rehwinkel, J., et al. (2014) · Nature · doi:10.1038/nature13590 · Cited by 557
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352 · cited 1×
“Incorporation of modified nucleosides into synthetic mRNA mitigates the immune response to some extent by mimicking endogenous mRNAs (Karikó et al. 2005; Durbin et al. 2016; Pardi et al. 2017; Richner et al. 2017; Freund et al. 2019).”
Background
Cited by
Innate immune mechanisms of mRNA vaccines
Verbeke, R., Hogan, M. J., Loré, K., & Pardi, N. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.014 · Cited by 501
Self-amplifying RNA vaccines for infectious diseases
Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308
An Update on Self-Amplifying mRNA Vaccine Development
Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288
Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157
“Furthermore, the presence of a template-encoded poly(A) tail showed to reduce antisense dsRNA byproducts, but not the amount of 3’ extended dsRNA byproducts [138].”
Metadata
- Authors
- Wu, M. Z., Asahara, H., Tzertzinis, G., & Roy, B.
- Venue
- RNA
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2020-01-03
- Volume
- 26
- Issue
- 3
- Pages
- 345-360
- ISSN
- 1355-8382 (ISSN-L)
- 1469-9001
- OpenAlex
- W2998568958
- Cited by
- 136
- References
- 13
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synthesis of low immunogenicity RNA with high-temperature in vitro transcription. https://app.cochat.ai/papers/10.1261/rna.073858.119
- The paper
- Wu, M. Z., Asahara, H., Tzertzinis, G., & Roy, B. (2020). Synthesis of low immunogenicity RNA with high-temperature in vitro transcription. RNA. https://doi.org/10.1261/rna.073858.119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.